BACKGROUND: Declines in percent predicted FVC (% predicted FVC), declines in 6-min walk distance (6MWD), and respiratory hospitalizations are events associated with disease progression and mortality in idiopathic pulmonary fibrosis. The incidence of multiple events in the same patient over 12 months of pirfenidone treatment is unknown.
Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible, and fatal fibrosing lung disease with a median survival of 2 to 3 years. 1, 2 The clinical course of IPF is variable and unpredictable. 2 During IPF progression, patients experience worsening dyspnea, hypoxemia, cough, and fatigue as lung function irreversibly declines. 1, 2 Pirfenidone is an oral antifibrotic agent approved for the treatment of patients with IPF that slows disease progression as demonstrated in pooled data from the phase III ASCEND (Study 016; NCT01366209) and CAPACITY (Studies 004 and 006; NCT00287716 and NCT00287729) trials. [3] [4] [5] To evaluate the potential benefits of continued treatment with pirfenidone in the context of disease progression, previous post hoc analyses of pooled data from ASCEND and CAPACITY examined outcomes in patients with IPF who experienced a disease progression event during the first 6 months of treatment. 6, 7 Patients receiving pirfenidone who experienced an initial absolute or relative decline in percent predicted FVC (% predicted FVC) $ 10% were less likely to experience further decline in lung function or death in the subsequent 6 months compared with those receiving placebo. 6 Similar trends for continued treatment benefit with pirfenidone were observed in patients who experienced an initial relative decline in 6-min walk distance (6MWD) $ 15% or a hospitalization from any cause. 6, 7 However, these prior analyses were limited to small subgroups defined by the initial disease progression event of a single type occurring in a limited period. A more global approach that evaluates all validated measures of disease progression over a broader observation period, including subsequent disease progression, could both confirm the progression of disease and would use a greater proportion of the available data. Such a broadly defined multiple events-driven end point for disease progression might yield a more complete characterization of treatment efficacy over time.
Therefore, the goal of this post hoc exploratory analysis of pooled data from the ASCEND and CAPACITY studies was to determine the incidence of multiple disease progression events in the first 12 months of pirfenidone treatment compared with placebo as an assessment of the durability of efficacy. In this analysis, disease progression comprised both the first occurrence and the subsequent occurrence of a disease progression event at any time during the follow-up period. To further assess the potential benefits of continued pirfenidone treatment in the context of IPF progression, the incidence of death following at least one disease progression event was also evaluated over 12 months of treatment compared with placebo.
Methods

Source Data and Study Population
Patients randomized to receive pirfenidone 2,403 mg/d or placebo in the ASCEND and CAPACITY studies were included in this study population. Eligibility criteria for these studies have been previously described. 3, 4 Available data for up to 12 months following treatment initiation were examined for progression events.
ASCEND and CAPACITY were conducted in accordance with the Declaration of Helsinki, as well as the relevant local legal and regulatory requirements of the countries in which the trials were conducted. Written informed consent was obtained from all patients prior to any study procedures, and study protocols were approved by the institutional review board or ethics committee at each participating center (additional details can be found in e-Appendix 1).
Disease Progression Events
In this pooled analysis, patients who had received pirfenidone 2,403 mg/d or placebo were evaluated for the incidence of the following disease progression events: relative decline in % predicted FVC $ 10%, absolute decline in 6MWD $ 50 m, respiratory-related hospitalization, and all-cause mortality. The cutoffs for declines in % predicted FVC and 6MWD were chosen to capture clinically meaningful changes. 8, 9 For the first decline in % predicted FVC $ 10%, the relative change was calculated as the change from baseline; after the first decline, the relative change was calculated from the % predicted FVC value recorded at the time of the most recent previous decline. For the first decline in 6MWD $ 50 m, the absolute change was calculated as the change from baseline; after the first decline, the absolute change was calculated from the 6MWD value recorded at the time of the most recent previous decline. These identification criteria were chosen to capture distinct events.
Respiratory-related hospitalizations were identified as previously described. 10 In ASCEND, hospitalizations were recorded as serious adverse events; two qualified pulmonologists retrospectively reviewed all hospitalizations independently, blinded to treatment group, and categorized each as either respiratory related or not respiratory related (a third pulmonologist independently adjudicated one discordant case). In CAPACITY, hospitalizations were a prespecified end point, with the reason selected by the local site investigator from the following: acute respiratory decompensation, IPF exacerbation, pneumonia, other respiratory related, and not respiratory related.
All-cause mortality was examined when death occurred as a first progression event or after at least one progression event. When more than one event occurred on the same date, the events were counted as a single disease progression event. For example, a patient who recorded declines in both % predicted FVC and 6MWD at the same visit (on the same calendar date) was considered to have experienced a single progression event.
Statistical Analyses
Except where noted otherwise, statistical comparisons were made on the basis of the overall population (all patients randomized to receive pirfenidone 2,403 mg/d or placebo). The proportions of patients with an event were compared using the c 2 test. Time-to-event comparisons were performed using a log-rank test, and proportional hazards regression was used to estimate the hazard ratio (HR [95% CI]). In the analysis of time to first event, patients with no events were censored; in the analysis of time to second event, patients with no event or a single event were censored. Missing data for % predicted FVC or 6MWD were not imputed.
Evaluations of multiple event times were performed as sensitivity analyses. 11 In the first analysis, the maximum number of events observed in any single patient (seven events) was modeled, and an average HR (95% CI) weighting across individual events was obtained. Because few patients had more than four events and estimates for more than four events were noted as unstable, a second analysis considered four or fewer events to confirm the conclusion.
To account for potential confounding resulting from the nonrandomized subgroups of patients who experienced at least one progression event, propensity score-adjusted analysis of deaths was performed as an additional sensitivity analysis. The propensity score model was constructed using a multivariable logistic regression model for treatment assignment (pirfenidone vs placebo) among patients who experienced at least one progression event with respect to demographic and baseline characteristics.
Results
Patients
A total of 1,247 patients who were in enrolled in the ASCEND and CAPACITY studies were included in this analysis; 623 patients received pirfenidone 2,403 mg/d and 624 patients received placebo (e -Fig 1) . Patients were predominantly men and white, with a median age of 68 years (Table 1) . Clinical characteristics were similar between patients who received pirfenidone and those who received placebo (Table 1) .
Incidence of Disease Progression Events
Declines in % predicted FVC and 6MWD comprised the majority of progression events (Fig 1) . The recurrence of the same event type within 12 months was infrequent. Fewer than 10% of patients in either the pirfenidone or placebo group experienced multiple progression events of the same type. Because % predicted FVC and 6MWD were collected at quarterly visits only, the ability to detect multiple events of the same type was limited.
A lower proportion of patients who received pirfenidone had more than one event compared with those who received placebo (17.0% vs 30.1%; P < .0001) (e- Fig 1) . Among 106 and 188 patients with more than one event who received pirfenidone and placebo, respectively, the most frequently observed sequences of events were 6MWD decline followed by % predicted FVC decline, % predicted FVC decline followed by 6MWD decline, 6MWD decline followed by a second 6MWD decline, and respiratory-related hospitalization followed by death (Fig 2) . These event sequences were observed in 14 (13.2%), 13 (12.3%), 10 (9.4%), and 4 (3.8%) patients in the pirfenidone group with more than one event and in 27 (14.4%), 26 (13.8%), 12 (6.4%), and 10 (5.3%) patients in the placebo group with more than one event, respectively.
In the pirfenidone group, 22 patients died; in the placebo group, 42 patients died over 12 months. The number of deaths increased with the number of preceding disease progression events, most notably in the placebo arm. Significantly fewer patients in the pirfenidone group died following one or more progression events compared with patients in the placebo group (13 patients [2.1%] vs 39 patients [6.3%]; P ¼ .0002) ( Table 2) . Death was frequently preceded by respiratory-related hospitalizations, % predicted FVC declines, and 6MWD declines; 10 of 13 deaths following one or more progression events (76.9%) in the pirfenidone group and 34 of 39 deaths following one or more progression events (87.2%) in the placebo group were preceded by at least one respiratory-related hospitalization (Table 3 ). Within the subset of patients with one or more progression events, demographic and baseline characteristics were well balanced between the pirfenidone and placebo groups; thus, consistent with the primary analysis, propensity score analysis indicated significantly fewer deaths after one or more progression events in the pirfenidone group than in the placebo group (data not shown).
Death was the first progression event in nine patients (1.4%) who received pirfenidone compared with three patients (0.5%) who received placebo (P ¼ .08) ( Table 2 ). The median (range) time from study initiation to death among these patients was 201 (28-357) and 110 (104-125) days in the pirfenidone and placebo groups, respectively. In the pirfenidone group, the causes of death as a first progression event were malignancies (n ¼ 3; small cell lung carcinoma, pancreas, bladder), respiratory/thoracic/mediastinal disorders (n ¼ 2; hypoxia, pulmonary hemorrhage), cardiac disorder (n ¼ 1; myocardial infarction), infection (n ¼ 1; sepsis), and general disorders/site conditions (n ¼ 2). In the placebo group, the causes of death as a first progression event were respiratory/thoracic/ mediastinal disorder (IPF; n ¼ 1), nervous system disorder (n ¼ 1; hemorrhagic stroke), and general disorder/site condition (n ¼ 1).
Patients who received pirfenidone had a significantly lower risk of experiencing a single progression event In this graph, events were treated as independent even if they were recorded on the same calendar date. Dark shaded "caps" on each column depict the percentage of patients who had a second progression event of the same type. 6MWD ¼ 6-min walk distance; %FVC ¼ percent predicted forced vital capacity. (Fig 3) . Patients in the pirfenidone group also had a significantly lower risk of experiencing a second progression event compared with placebo (HR, 0.53 [95% CI, 0.42-0.67]; P < .0001). Sensitivity analysis of multiple event times supported the analyses of time to first event and time to second event. The weighted average HR was 0.70 (95% CI, 0.61-0.81) in the analysis of up to seven events and 0.68 (95% CI, 0.59-0.78) in the analysis of up to four events. Because approximately 60% of events in the multiple-events analysis were first events and another approximately 25% were second events, the heaviest weight was applied to the first event, less was applied to the second event, and almost no weight was applied to events after the second; therefore, the estimates are most similar to the time-to-first-event analysis.
Although lack of efficacy was not a protocol-specified reason for treatment withdrawal, the reasons for early discontinuation were similar among patients with or without at least one disease progression event (e- Table 1 ). The exception is the higher numbers of lung transplant or death cited as reasons for discontinuation among patients with disease progression events, as would be expected. These findings suggest that a lack of efficacy was not a major driver of early treatment discontinuation and that the disease progression events included in this analysis are reasonably representative of disease course during the period studied.
Discussion
Among 1,247 patients who received pirfenidone 2,403 mg/d or placebo in the ASCEND and CAPACITY studies, 294 (23.6%) experienced multiple progression events during 12 months of treatment with pirfenidone or placebo. Significantly fewer patients who received pirfenidone in the phase III trials experienced more than one disease progression event compared with placebo. Death following one or more progression events was less frequent in the pirfenidone group than in the placebo group. The risk of both first and second progression events was significantly lower in patients who received pirfenidone than in those who received placebo, and sensitivity analyses of the time to multiple events supported these findings.
Previous analyses have shown that all-cause and respiratory-related hospitalizations are predictive of short-term mortality in patients with IPF. 6, 12, 13 Notably, in a pooled analysis of six clinical trials in IPF (including ASCEND and CAPACITY), respiratory-related hospitalization was associated with a 30-fold increase in mortality risk. 13 Consistent with these findings, 76.9% and 87.2% of deaths following one or more progression events in this analysis in the pirfenidone and chestjournal.org placebo groups, respectively, were preceded by respiratory-related hospitalizations.
Pirfenidone treatment is associated with a reduction in all-cause mortality. 14 The findings of this analysis were consistent for deaths that occurred after one or more progression events; fewer patients in the pirfenidone group died over 12 months than in the placebo group. Although more patients who received pirfenidone died as a first progression event than in the placebo group (9 vs 3), we recognize that the causes of death in these patients and timing varied widely (day 28 to day 357). Although the small numbers make interpretation difficult, the data do not suggest a common underlying pathophysiology in these cases.
The findings of this analysis build on previous singleevent definitions of disease progression to demonstrate the durability of the clinical benefit of pirfenidone in IPF. 6, 7 With disease progression defined as either a single occurrence of a decline in % predicted FVC, decline in 6MWD, or all-cause hospitalization in the first 6 months of treatment, patients who received pirfenidone were less likely to experience further decline or death than patients who received placebo. 6, 7 Unlike these prior studies, however, this analysis observed disease progression events occurring at any time over the entire follow-up duration.
In clinical practice, evidence of disease progression can create uncertainty regarding treatment, and some patients and physicians may be inclined to stop or switch therapies. In this analysis, patients who received pirfenidone and experienced a disease progression event at any time over 12 months of observation were at lower risk for additional progression events and mortality. These data support the continuation of pirfenidone treatment despite evidence of disease progression.
Ethical and practical considerations in the design of future clinical trials in IPF will likely entail allowing patients in the control arms to receive antifibrotic therapy. 15 Disease progression will occur at slower rates in control arms with background antifibrotic therapy than in the placebo arms of past trials. To detect differences between treatment arms in the end points of FVC decline and mortality, trials may require longer durations, larger enrollment populations, or both. New end points, such as a multiple event-driven end point, that more completely characterize disease progression and help to assess durability of efficacy may help to meet this challenge. 16 This analysis has several limitations. This was a post hoc exploratory analysis of disease progression in a clinical trial population; thus, the findings should be interpreted cautiously. Variability in % predicted FVC and 6MWD could contribute to measurement error in determining the occurrence of a disease progression event, although these measures are reproducible and represent clinically meaningful and generally irreversible declines. 1, 6, 17 Quarterly assessment of % predicted FVC and 6MWD reduces the accuracy of timing for detecting disease progression, and the grouping of events observed during the same visit as a single event may further reduce the sensitivity of each efficacy variable.
Conclusions
Pirfenidone treatment significantly reduced the incidence of multiple disease progression events compared with placebo. Unlike previous analyses with single events defining disease progression, this analysis evaluated the treatment benefit of pirfenidone in the context of multiple disease progression events occurring any time over 12 months. This analysis provides a more global assessment of the benefits of pirfenidone therapy, including its ongoing salutary effects after a single disease progression event. A similar multiple eventdriven end point in clinical trials could provide a more complete characterization of a drug's efficacy, including insight into the durability and scope of treatment benefit. This analysis therefore provides a basis for further exploration of new disease progression end points for potential use in future clinical trials, which will invariably include standard-of-care control arms, with many patients receiving established antifibrotic therapy.
